OBJECTIVE: To examine cross-sectionally the ability of digital x-ray radiogrammetry (DXR) to assess bone loss in RA compared with a manual radiograph scoring technique and the relationship of both these scores with other disease indices. METHODS: Consecutive consenting subjects attending the RA clinic were enrolled. Subjects were sent for x-ray; had their demographic details recorded; completed a self assessment questionnaire, which collected data on early morning stiffness, pain, patient global assessment and included a modified health assessment questionnaire (HAQ); had blood taken for erythrocyte sedimentation rate measurement and were assessed by author JC, a trained nurse, who recorded an assessor's global assessment (AGA) and 28 point tender and swollen joint counts. All x-ray films were scored manually using the modified Sharp scoring technique by a single observer and 20 films were randomly selected for rescoring by 3 readers. All films were assessed using the Pronosco X-Posure System version 2.0. Analysis was performed in 225 subjects and included chi-squared tests, independent t-tests, multiple linear regression and partial correlations as appropriate. The precision of scoring techniques was estimated by calculating the smallest detectable difference (SDD), the coefficient of variation (CV) and the coefficient of repeatability (CR) from Bland & Altman plots. RESULTS: The precision of DXR depending on the index assessed varied from SDD: 0.002 to 0.9; CV: 0.09% to 5.9%; CR: 0.002 to 0.792.These figures were better than that of the intra and inter-observer Sharp scores SDD = 73.9; CV = 27.8%; CR: 33.0 to 47.6).
Introduction
Many advances have been made in uncovering the pathogenesis of rheumatoid arthritis and this has led to the introduction of new therapies. Cytokines produced by macrophages, in particular TNFα have been found in higher concentrations in rheumatoid joints (1;2) . This has led to development of therapies directed against TNFα and its receptors, which have shown to slow radiographic joint damage, but these are expensive and can have serious side effects (3) (4) (5) (6) . It would be useful if these and other disease modifying drugs could be specifically targeted at an early stage of disease to those subjects who are unresponsive to safer and cheaper drugs and are having ongoing joint damage.
Current techniques of assessing long-term disease progression in rheumatoid arthritis (RA), although useful in comparing drug treatments in clinically controlled trials, are not very effective in assessing RA in individual subjects. Accordingly they are very rarely used as part of standard day-to-day clinical practice by rheumatologists (7) .
It is necessary to use various imaging techniques to assess structural damage. While there is interest in using MRI (8) and imaging ultrasound(9;10) to assess joint damage including cartilage loss and erosion counts, the most widely used methods are a variety of plain film x-ray scoring techniques. The Sharp scoring method (11) is such a technique and in its modified forms such as that suggested by van Heijde (12) , is commonly used in clinical trials to assess erosions and joint space narrowing for joints of both the hands and feet.
Since erosive damage of the peri-articular bones is believed to be largely irreversible, the use of such an end-point clinically might be considered to have limited benefit with treatment always lagging behind disease progression. However, a measurement technique that showed a strong relationship with joint damage, which is in itself related to long-term functional status, might have real clinical value.
Peri-articular bone loss is the earliest radiological feature of RA. Using quantitative assessment of hand bone mass as a surrogate, bone loss can be seen to occur early in the disease and predate erosive damage (13;14) . Peripheral bone mass can be quantified by a number of techniques in RA including dual energy X-ray absorptiometry (DXA) (13) (14) (15) , quantitative ultrasound(9;10;16) and possibly MRI (8) . DXA is most widely used for estimating in vivo total hand BMD but may also be used to assess BMD specifically at the metacarpals (14) . Recently an improved method of radiogrammetry has been introduced using digitised plain hand radiographs (17) to measure bone density, metacarpal index, cortical thickness and porosity with high precision (18) .
In this study we have examined the ability of digital x-ray radiogrammetry (DXR) to assess bone loss in RA, compared the results with a manual plain radiograph scoring techniquethe modified Sharp score(19) -and examined the relationship of both methods to other indices of disease activity and progression in RA.
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Methods
The study was carried out at the Osteoporosis Research Unit, Aberdeen. The Grampian Research Ethics Committee granted ethical approval.
Subjects attending the RA clinic were provided with information about the study, which included an information leaflet. Consecutive, consenting subjects were enrolled onto the study. Subjects also underwent an x-ray of their hands if such an x-ray had not been Subjects' demographic details were recorded and a self-assessment questionnaire was completed, which included data of the duration of early morning stiffness (EMS); pain, as assessed on a 10cm horizontal visual analogue scale (VAS) and a patient global assessment (PGA) of disease activity, as assessed on a 10 cm horizontal VAS. A modified health assessment questionnaire (HAQ) was also administered (20) . Blood was also taken from subjects and the ESR measured in mm after a 1-hour sample frame. Subject case notes were audited and current medications and dosages, rheumatoid factor positivity, duration of disease and the presence or absence of erosions noted on the database. "Physician" assessments were also carried out by JS, a fully trained research nurse and included an assessor global assessment (AGA) of disease activity as assessed on a 10cm horizontal VAS, and a 28-point tender and/or swollen joint count. If appropriate the subjects were then asked to attend for a plain film x-ray to be taken of both hands. Only those subjects that had a relevant x-ray taken were assessed as part of this study.
Author WBJ scored all the available hand x-rays using the modified Sharp scoring method and the results were recorded. 20 randomly selected subjects were re-scored by WBJ a week after the initial assessment to allow calculation of short-term intra-observer variation.
Inter-observer variation was calculated by examining 20 x-rays randomly selected for rescoring by 3 observers (DC, DMR and WBJ).
All the hand x-rays were then assessed using the Pronosco X-Posure System version 2.0 (Sectra Medical Systems, Sweden) (18;21-24) . This system provides the following measurements: DXR-BMD -(Bone mineral density); Porosity (POR); Metacarpal Index (MCI); Cortical Thickness (CT); Bone Width (BW). The Pronosco X-Posure System requires plain x-ray films. The x-rays films of the subjects in this study were of both hands on the same film. To evaluate x-rays using DXR the x-ray of each hand was separately scanned in and then analysed. BMD is calculated using formulae after assessment of the bone volume per area, assuming a cylindrical bone (18) All data was entered into a spreadsheet and analysed using SPSS 11.0.1 (SPSS Inc, USA) and Microsoft Excel (Microsoft Corp, USA). Tests used included chi-squared tests, independent t-tests, multiple linear regression analysis (MLR) and partial correlation as appropriate. The precision was estimated by calculating the smallest detectable difference (SDD) and the standardised coefficient of variation (CV). The reproducibility of the repeated measurements was assessed using Bland & Altman plots and coefficients of repeatability were calculated. Correlation coefficients were compared using Fisher's z transformation.
Results

Subject flow and comparison
The flow of subjects through the study is shown in Figure 2 . 537 subjects were on the original database but only 225 met the entry requirements. Demographics and disease activity indices for the current study group were compared with the total study population in Table 1 . We found the HAQ score was significantly lower (p=0.026) in the study group than in the whole population and disease duration was significantly shorter (p=0.023) but there were no other significant differences between the groups.
Precision Sharp scores
The mean (+/-1SD) Sharp Scores for the study population was 79.38 (+/-53.45). The intraobserver variation calculations for the modified Sharp scoring techniques were CV = 7.2%. The intra-observer precision values for the different DXR parameters scored on the same 20 radiographs assessed on two separate occasions 2 months apart are summarised in Table 2 .
Of the DXR measurements porosity appears to be the least precise measurement while bone width and cortical thickness are the most precise. The co-efficient of repeatability ranged from 0.002 to 0.792 for the DXR measurements.
Correlations between Sharp scores and DXR measurements Table 3 shows the Partial correlations between Sharp scores and DXR measurements. In male subjects correlation between DXR-MCI and the modified Sharp score and its component scores appears to be weaker than that in female subjects although the differences are not significant (p > 0.05 for all coefficients). The derived porosity index and bone width did not relate to any aspect of the Sharp index.
Correlation of radiological measures of disease severity with clinical disease activity measurements Table 4 show the correlation between DXR measurements, Sharp scores and clinical measures of disease activity. In female subjects for DXR measurements the only significant correlations seen were with HAQ scores (r=-0.218, P=0.008). In contrast Sharp 
Discussion
The precision results clearly indicate that DXR measurements are much more reproducible than Sharp scores which vary greatly not only between observers but also when re-scored by the same observer even a week later. The precision of DXR measurements in this study is better than that reported by Jorgensen et al.(18) . This discrepancy is most likely to be due to the fact that we are simply measuring noise in the system, since the same radiograph is used each time. Perhaps a truer estimate would be given if 2 x-rays were taken at the same time point and used for calculation of precision. The precision of the modified Sharp score was lower than that reported by Sharp et al.(25) , who found an inter-observer CV of 17%. However this may be due to the limited experience of two of the scorers or may be due to the long duration of disease making reading of the x-ray more difficult. However a recent comparison of intra-and inter-observer variation by Sharp et al. has shown figures for the SDD which are very similar to those we were able to achieve (26).
Bone loss is an early feature of RA and precedes the permanent and irreversible erosive changes that occur (13;14) . The Pronosco device can measure bone loss at the metacarpals, which are in the region most commonly affected by RA and therefore may be able to identify individuals requiring a change in therapy before any irreversible joint damage occurs. It has been well established that BMD is reduced in RA subjects and the degree of loss is related to disease activity. Daragon et al found significantly reduced BMD of the whole hand using DEXA at 6 months in RA subjects compared to subjects with other rheumatic diseases (27). This study has demonstrated that both DXR and Sharp score measurements are related more to disease severity than to current disease activity. This has also been shown previously (28). DXR measurements are as good as Sharp scores in predicting HAQ and may even be better in male subjects. Their predictive value may not be so good in females due to other confounding factors which influence the measurement of bone mass including menopausal state and pre-disease bone mass status. Of the various DXR parameters available, BMD seems numerically to correlate best with modified Sharp scores but the differences between the correlation coefficients and the other DXR parameters are not statistically significant. In our study DXR measurements are related to long-term disease activity in RA and therefore serial measurements in individual subjects may have the ability to assess response to therapy and this may be possible over short enough time periods to improve patient care, due to the high precision of the technique. Indeed a recent study by Jensen et al (30) has demonstrated that during a two year period measurements of DXR BMD showed more rapid changes in those with active compared to inactive disease and was also able to distinguish those with erosive as compared to non-erosive RA. A recent pilot longitudinal study from our own centre in subjects with early RA has identified how a measurement of the rate of change of DXR BMD in the first year of follow-up may be able to identify those who become erosive by 4 years of disease with high specificity and reasonable sensitivity (31) . DXR is simple to use, does not require intensive training and if used in a clinical setting may have the ability to quickly and cheaply identify subjects not responding to standard therapy or may allow selection of subjects who would benefit from more aggressive therapy with newer, more expensive treatments at an earlier stage of disease.
Such a hypothesis will require testing in a formal prospective clinical trial.
In summary we describe a method of assessing peripheral bone mass in RA that could have use in routine clinical care unlike the time consuming and rather imprecise measurement of joint space narrowing and erosion scores such as the Sharp score. Longitudinal studies will be required to determine the value of the technique in assessing suitability of subjects for expensive biological agents which can effectively limit joint destruction and bone loss. (Age at x-ray and weight were used as controlling variables). 
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